
In an era of targeted therapies, patients with cancer in resource‐constraint countries continue to struggle to find affordable care. The present study is a multicenter prospective single‐arm study. Patients with expected delay in surgery, unresectable or metastatic cancers, and patients not suitable for surgery or conventional chemotherapy were included. Oral methotrexate 15 mg/m2 once a week and oral celecoxib 200 mg twice daily was used for metronomic therapy. At 8 weeks, a clinically complete response was seen in 2.5%, partial response in 46.6%, stable disease in 39.8%, and disease progression in 11%. Size less than 4 cm, alveolobuccal subsite, and well‐differentiated histology were significantly associated with no disease progression...
Like
Save
Share